The synergistic effect of inhibiting both PRMT1 and SMARCA4 (as with GSK-PTi and BBAi-1) in SMARCA4-R1157W mutant CRC cells may shed new light on the possibility of precision therapy for CRC patients with SMARCA4-R1157W mutation. This evidence concerns the gene SMARCA4 and colorectal carcinoma.